Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Completed · Phase 2

Conditions studied: Colorectal Cancer

In brief

Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have metastatic or locally recurrent colorectal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Key facts

Study ID

NCT00005085

Run by

National Cancer Institute (NCI)

People needed

37

Starts

2000-02-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Atlanta Cancer Care — Atlanta, Georgia, United States
• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States
• New York Medical College — Valhalla, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.